Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.

@article{Alphandry2015CancerTU,
  title={Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.},
  author={Edouard Alphand{\'e}ry and Pierre Grand-Dewyse and Raphael Lef{\`e}vre and Chalani Mandawala and Mickael Durand-Dubief},
  journal={Expert review of anticancer therapy},
  year={2015},
  volume={15 10},
  pages={1233-55}
}
Several nanoformulated anti-cancer substances are currently commercialized or under development. Pre-clinical and clinical results have revealed better properties, that is, larger efficacy and lower toxicity for these substances than for conventional anti-cancer treatments. Here, we review the development of several of these substances such as Marqibo, Myocet, Doxil, DaunoXome, MM398, MM302, Mepact, Versamune, Thermodox, Depocyt, Livatag, Abraxane, Eligard, Opaxio, Zinostatin Stimalamer (SMANCS… CONTINUE READING